INTERLEUKIN 1β LEVEL AND C- REACTIVE PROTEIN ROLES IN PRIMARY MYELOFIBROSIS PATIENTS TREATED WITH HYDROXYUREA AND RUXOLITINIB

@inproceedings{Matti2017INTERLEUKIN1L,
  title={INTERLEUKIN 1β LEVEL AND C- REACTIVE PROTEIN ROLES IN PRIMARY MYELOFIBROSIS PATIENTS TREATED WITH HYDROXYUREA AND RUXOLITINIB},
  author={Bassam Francis Matti and Shahla'a Fadhil Sabir and Maysaa Ali Abdul Khaleq and Marwah Hasan Al Kaabi},
  year={2017}
}
Primary Myelofibrosis (PMF) is one of development of the myeloproliferative neoplasms that occurs during change in the DNA of a single hematopoietic stem cell. About 50 % of people with MF have an alteration called V617F JAK2 that initiate in the Janus kinases (JAK2) gene. The gene alteration causes unusual signaling in the JAK pathway, which regulates the production of blood cell. There is many theories suggesting the deregulated irritation and immune genes have a role in patients with… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Efficacy and Safety of Ruxolitinib in the Treatment of Patients with Myelofibrosis

Cecilia Arana Yi, Constantine S Tam, Srdan Verstovsek
  • Future Oncol
  • 2015
VIEW 1 EXCERPT

MMP2gene-1562C/T poly morphisms in JAK2V617 F positive myelofibrosis disorder

So Sag, O Gorukmez, M. Twe
  • Asian Pac J Cancer Prev 2015;16:443-9
  • 2015
VIEW 1 EXCERPT

The JAK-STAT pathway and hematopoietic steam cells from the JAKV617F perspective.

Staerk, Judith, Constantinescu, N Stefan
  • JAK-STAT
  • 2014
VIEW 2 EXCERPTS

Guideline for the diagnosis and management of myelofibrosis

JT Reilly, MF Mc Mullin, +3 authors A etal.Duncombe
  • Br.J.Haematol
  • 2012
VIEW 1 EXCERPT